China Pharma Holdings, Inc. reported its financial results for the six months ended June 30, 2025, revealing a revenue of $2.16 million, a decrease of 5.8% compared to $2.29 million in the same period of 2024. The company experienced a gross loss of $0.22 million, significantly improved from a gross loss of $1.31 million in the prior year, reflecting a gross loss margin of 10.3% compared to 56.9% in 2024. The net loss for the period was $1.31 million, down from $2.39 million a year earlier, with loss per share improving to $0.40 from $1.63.
The company’s operational metrics showed a notable shift, with total current assets decreasing to $2.70 million from $3.27 million at the end of 2024. Trade accounts receivable increased to $0.27 million, while inventories decreased to $1.68 million from $2.27 million. The allowance for credit losses remained stable at $13.64 million, indicating ongoing challenges in receivables management. The company’s cash and cash equivalents stood at $0.63 million, consistent with the previous period.
Strategically, China Pharma has been focusing on enhancing its product offerings and operational efficiencies. The company has been actively involved in the consistency evaluation of its generic drugs, with one of its flagship products, Candesartan tablets, successfully passing evaluation in August 2023. Additionally, the company is exploring the comprehensive healthcare market, launching products such as Noni enzyme supplements and medical masks in response to changing health needs in China.
Looking ahead, China Pharma's management has expressed concerns regarding its ability to continue as a going concern, citing accumulated deficits and ongoing operational losses. The company plans to enhance its sales model, strengthen accounts receivable collections, and explore strategic alternatives to improve its financial position. However, there is no assurance that these initiatives will be successful, and the company may need to seek additional financing to support its operations.
About CHINA PHARMA HOLDINGS, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.